Severe liver disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients with liver failure who met the inclusion criteria were screened in the established and continuously maintained clinical database of artificial liver therapy [Ethics Approval No.2019 (668)], and patients with hepatitis B-related ACLF (HBV-ACLF) were included in this study. The diagnosis of HBV-ACLF was in accordance with the diagnostic criteria of ACLF of China Severe Hepatitis Group (COSSH) . (1) Age = 14 years old, male or female; (2) History of chronic hepatitis B virus infection; (3) Total bilirubin = 12 mg/dL (205 umol/L) and PT-INR = 1.5; (4) The treatment model of artificial liver therapy was PA followed by PE; (5) Patients agreed to be included in the clinical database of artificial liver therapy [Ethics Approval No.2019 (668)].
Exclusion criteria
Exclusion criteria: (1) Combined with hematological malignant diseases, such as hematological tumor and bone marrow suppression; use of drugs with definite bone marrow suppression or promoting bone marrow hematopoiesis; (2) Congenital or acquired abnormalities of coagulation factors and fibrinogen causing PLT reduction; (3) Disseminated intravascular coagulation; (4) Use of heparin drugs within 7 days before artificial liver treatment; (5) Use of anti-PLT drugs within 7 days before artificial liver treatment; (6) Infusion of PLT within 7 days before ALSS; (7) Bleeding within 7 days before artificial liver treatment; (8) Previous splenectomy; (9) After transplantation of liver and other organs; (10) Pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of a bleeding event; Changes in platelet count; | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic characteristics;Disease characteristics; | — |
Countries
China
Contacts
Center of Infectious Diseases, West China Hospital of Sichuan Universit